Page last updated: 2024-12-06

fenproporex

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

fenproporex: was minor descriptor; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID61810
CHEMBL ID2105566
CHEBI ID134837
SCHEMBL ID157687
MeSH IDM0085875

Synonyms (39)

Synonym
femproporex [inn-spanish]
fenproporexum [inn-latin]
dea no. 1575
fenproporex [inn:dcf]
einecs 239-772-0
fenproporex
DB01550
16397-28-7
CHEBI:134837
3-(1-phenylpropan-2-ylamino)propanenitrile
15686-61-0
D07947
fenorex (tn)
fenproporex (inn)
unii-w0194s5foa
3-((1-methyl-2-phenylethyl)amino)propiononitrile
w0194s5foa ,
einecs 240-444-4
desobesi
CHEMBL2105566
j268.797f
fenorex
femproporex
fenproporex [inn]
(+/-)-3-((.alpha.-methylphenethyl)amino)propionitrile
fenproporex [mi]
fenproporex [who-dd]
SCHEMBL157687
DTXSID0043921
IQUFSXIQAFPIMR-UHFFFAOYSA-N
(.+/-.)-n-2-cyanoethylamphetamine
propionitrile, 3-((.alpha.-methylphenethyl)amino)-, (.+/-.)-
propanenitrile, 3-[(1-methyl-2-phenylethyl)amino]-, (.+/-.)-
(.+/-.)-3-[(.alpha.-methylphenethyl)amino]propionitrile
n-(2-cyanoethyl)amphetamine
3-[(1-methyl-2-phenylethyl)amino]propanenitrile #
3-[(1-methyl-2-phenylethyl)amino]propiononitrile
Q5443577
n-2-cyanoethylamphetamine

Research Excerpts

Overview

Fenproporex is a sympathomimetic agent with a pharmacological profile similar to that of amphetamine. It is rapidly converted into amphetamine in vivo.

ExcerptReferenceRelevance
"Fenproporex is an amphetamine-based anorectic which is rapidly converted into amphetamine in vivo. "( Evaluation of Na+, K+-ATPase activity in the brain of young rats after acute administration of fenproporex.
Cardoso, MR; Cunha, MJ; Ferreira, AG; Ferreira, GK; Gonçalves, CL; Quevedo, J; Rezin, GT; Scaini, G; Schmitz, F; Streck, EL; Varela, RB; Wyse, AT,
)
1.79
"Fenproporex (Fen) is an amphetamine-based anorectic; amphetamine use causes a broad range of severe cognitive deficits and anxiogenic-like effects. "( Effects of chronic administration of fenproporex on cognitive and non-cognitive behaviors.
Bavaresco, DV; Budni, J; Furlanetto, CB; Gonçalves, CL; Quevedo, J; Streck, EL; Valvassori, SS; Varela, RB, 2015
)
2.13
"Fenproporex is an amphetamine-based anorectic and it is rapidly converted in vivo into amphetamine. "( Inhibition of acetylcholinesterase activity in brain and behavioral analysis in adult rats after chronic administration of fenproporex.
Cardoso, MR; Constantino, LS; Deroza, PF; Ferreira, GK; Ghedim, FV; Gonçalves, CL; Quevedo, J; Resende, WR; Rezin, GT; Scaini, G; Streck, EL; Valvassori, SS; Zugno, AI, 2012
)
2.03
"Fenproporex is a sympathomimetic agent with a pharmacological profile similar to that of amphetamine. "( A contemporaneous finding of fenproporex in a polydrug suicide.
Bell, RR; Crookham, SB; Dunn, WA; Grates, KM; Reiber, TM, 2001
)
2.04

Treatment

The fenproporex treatment increased locomotor behavior in saline-treated rats under reversion and prevention model. Treatment also increased the number of fetuses presenting small kidneys and cervical ribs. The treatment did not influence the mobility in the forced-swimming test.

ExcerptReferenceRelevance
"The fenproporex treatment increased locomotor behavior in saline-treated rats under reversion and prevention model, and ω3 fatty acids prevented fenproporex-related hyperactivity."( Omega-3 fatty acids alter behavioral and oxidative stress parameters in animals subjected to fenproporex administration.
Ferreira, GK; Gomes, LM; Gonçalves, CL; Model, CS; Quevedo, J; Rezin, GT; Scaini, G; Steckert, AV; Streck, EL; Valvassori, SS; Varela, RB, 2014
)
1.1
"Fenproporex treatment also increased the number of fetuses presenting small kidneys and cervical ribs."( Developmental exposure to fenproporex: reproductive and morphological evaluation.
Baroneza, JE; Faria, MJ; Moreira, CQ; Moreira, EG; Oliveira, RJ, 2005
)
1.35
"Treatment with fenproporex increased ambulation of dams in the open-field test and did not influence the mobility in the forced-swimming test."( Developmental exposure to fenproporex: reproductive and morphological evaluation.
Baroneza, JE; Faria, MJ; Moreira, CQ; Moreira, EG; Oliveira, RJ, 2005
)
0.97

Toxicity

ExcerptReferenceRelevance
" Abuse potential and amphetamine-like adverse effects are causes for concern."( Safety and efficacy of fenproporex for obesity treatment: a systematic review.
de Oliveira, AC; Paumgartten, FJ; Pereira, SS, 2016
)
0.74

Pharmacokinetics

ExcerptReferenceRelevance
"The authors observed that oral administration of FEN resulted in significant amounts of FEN and AMP in oral fluid, showing that oral fluid could be a biological matrix suitable for pharmacokinetic studies for both analytes."( Fenproporex and amphetamine pharmacokinetics in oral fluid after controlled oral administration of fenproporex.
Boehl, PO; Cássia Mariotti, Kd; Comiran, E; De Boni, RB; Duarte, Pdo C; Fröehlich, PE; Limberger, RP; Pechansky, F; Souza, DZ, 2012
)
1.82
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
amphetaminesAmines that constitute a class of central nervous system stimulants based on the structure of the parent amphetamine 1-phenylpropan-2-amine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (12.12)18.7374
1990's2 (6.06)18.2507
2000's9 (27.27)29.6817
2010's18 (54.55)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 60.12

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index60.12 (24.57)
Research Supply Index3.81 (2.92)
Research Growth Index4.93 (4.65)
Search Engine Demand Index94.97 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (60.12)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (10.00%)5.53%
Reviews3 (7.50%)6.00%
Case Studies5 (12.50%)4.05%
Observational0 (0.00%)0.25%
Other28 (70.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]